Study shows multiple-dose, targeted radiation more effective for treating pituitary tumors

(Houston Methodist) A recent patient study at Houston Methodist Hospital proved that multiple small doses of highly focused radiation therapy is safer and more effective than a single larger dose of radiation at destroying pituitary gland tumors.
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news

Related Links:

CONCLUSIONS: The present study identified hub genes and pathways in HCC that may be potential targets for diagnosis, treatment and prognostic prediction. PMID: 32200915 [PubMed - in process]
Source: The American Journal of the Medical Sciences - Category: General Medicine Authors: Tags: Am J Med Sci Source Type: research
ncaroli C Adenohypophyseal tumors, which were recently renamed pituitary neuroendocrine tumors (PitNET), are mostly benign, but may present various behaviors: invasive, “aggressive” and malignant with metastases. They are classified into seven morphofunctional types and three lineages: lactotroph, somatotroph and thyrotroph (PIT1 lineage), corticotroph (TPIT lineage) or gonadotroph (SF1 lineage), null cell or immunonegative tumor and plurihormonal tumors. The WHO 2017 classification suggested that subtypes, such as male lactotroph, silent corticotroph and Crooke cell, sparsely granulated somatotr...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Review Source Type: research
i Chiara Villa Adenohypophyseal tumors, which were recently renamed pituitary neuroendocrine tumors (PitNET), are mostly benign, but may present various behaviors: invasive, “aggressive” and malignant with metastases. They are classified into seven morphofunctional types and three lineages: lactotroph, somatotroph and thyrotroph (PIT1 lineage), corticotroph (TPIT lineage) or gonadotroph (SF1 lineage), null cell or immunonegative tumor and plurihormonal tumors. The WHO 2017 classification suggested that subtypes, such as male lactotroph, silent corticotroph and Crooke cell, sparsely granulated soma...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Review Source Type: research
Pituitary adenomas, accounting for 15% of diagnosed intracranial neoplasms, are usually benign and pharmacologically and surgically treatable; however, the critical location, mass effects and hormone hypersecretion sustain their significant morbidity. Approximately 35% of pituitary tumors show a less benign course since they are highly proliferative and invasive, poorly resectable, and likely recurring. The latest WHO classification of pituitary tumors includes pituitary transcription factor assessment to determine adenohypophysis cell lineages and accurate designation of adenomas, nevertheless little is known about molecu...
Source: Frontiers in Endocrinology - Category: Endocrinology Source Type: research
Discussion of the Evolutionary Genetics of Aging Thymic Involution Contributes to Immunosenescence and Inflammaging The Potential for Exosome Therapies to Treat Sarcopenia Correlations of Mitochondrial DNA Copy Number and Epigenetic Age Measures Evidence for PASK Deficiency to Reduce the Impact of Aging in Mice The Aging Retina, a Mirror of the Aging Brain Evidence for Loss of Capillary Density to be Important in Heart Disease Aspects of Immune System Aging Proceed More Rapidly in Men Deacetylation of the NLRP3 Inflammasome as a Way to Control Chronic Inflammation Transplantation of Senescent Cells is an ...
Source: Fight Aging! - Category: Research Authors: Tags: Newsletters Source Type: blogs
Cancers, Vol. 12, Pages 308: Exploring the Role of Novel Medical Therapies for Aggressive Pituitary Tumors: A Review of the Literature—“Are We There Yet?” Cancers doi: 10.3390/cancers12020308 Authors: Lamb Sim McCormack Aggressive pituitary tumors account for up to 10% of pituitary tumors and are characterized by resistance to medical treatment and multiple recurrences despite standard therapies, including surgery, radiotherapy, and chemotherapy. They are associated with increased morbidity and mortality, particularly pituitary carcinomas, which have mortality rates of up to 66% at 1 year a...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Review Source Type: research
Publication date: Available online 10 December 2019Source: Artificial Intelligence in MedicineAuthor(s): Sarah Ali Abdelaziz Ismael, Ammar Mohammed, Hesham HefnyAbstractCancer is the second leading cause of death after cardiovascular diseases. Out of all types of cancer, brain cancer has the lowest survival rate. Brain tumors can have different types depending on their shape, texture, and location. Proper diagnosis of the tumor type enables the doctor to make the correct treatment choice and help save the patient's life. There is a high need in the Artificial Intelligence field for a Computer Assisted Diagnosis (CAD) syste...
Source: Artificial Intelligence in Medicine - Category: Bioinformatics Source Type: research
ardo Cristina Lamas Ignacio Aranda Antonio Picó The classification of pituitary neuroendocrine tumors (PitNETs) subtypes continues generating interest. In 2017, the World Health Organization (WHO) proposed considering the immunohistochemical (IHC) analysis of pituitary-specific transcription factors (TF) for their typification. The present study targeted the quantification of pituitary-specific TF (TPIT, PIT-1, SF-1, GATA2, ESR1) gene expression by RT-qPCR to overcome the shortcomings of IHC and to complement it. We analyzed 251 tumors from our collection of PitNETs and performed additional IHC studies in ...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Article Source Type: research
Modern Pathology, Published online: 04 December 2019; doi:10.1038/s41379-019-0418-2Prognostic value of mitotic checkpoint protein BUB3, cyclin B1, and pituitary tumor-transforming 1 expression in prostate cancer
Source: Modern Pathology - Category: Pathology Authors: Source Type: research
__________ Just a heads-up about a great event later this week in Dublin, Ireland, for those working on virtual and augmented reality and healthcare innovation. When: Thu Dec 5, 2019 8:00 am — Fri Dec 6, 2019 5:00 pm. Where: Davenport Hotel Featured sessions include: Day 1 – Thursday, December 5th, 2019 9:00am‑9:30am Introductions, Welcome and Setting The Stage Robert Fine, Executive Director, International Virtual Reality and Healthcare Association (IVRHA) 9:30am-10:30am Keynote Presentation:  Virtual Reality and Healthcare: The Past, The Present and The Future Dr. Walter Gree...
Source: SharpBrains - Category: Neuroscience Authors: Tags: Cognitive Neuroscience Education & Lifelong Learning Health & Wellness Technology augmented reality Dublin healthcare healthcare innovation virtual-reality Source Type: blogs
More News: Cancer | Cancer & Oncology | Hospitals | Pituitary Tumor | Radiation Therapy | Study